BusinessCempra Receives Complete Response Letter From FDA For Solithromycin NDAsBy Nasdaq OMXDec 29, 2016, 11:55 AM UTC
BusinessEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Cempra, Inc. - CEMPBy Nasdaq OMXDec 27, 2016, 7:53 PM UTC
BusinessCempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to PresidentBy Nasdaq OMXDec 12, 2016, 2:01 PM UTC
BusinessScott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Cempra, Inc. (NASDAQ: CEMP) Securities CaseBy Nasdaq OMXDec 5, 2016, 6:35 PM UTC
BusinessToyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s SolithromycinBy Nasdaq OMXDec 5, 2016, 1:01 PM UTC
BusinessScott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Cempra, Inc. (NASDAQ: CEMP) Securities CaseBy Nasdaq OMXNov 14, 2016, 4:36 PM UTC
